跳至主要内容
临床试验/NL-OMON52864
NL-OMON52864招募中3 期

asal High-Flow Therapy to treat COPD exacerbations: a matter of monitoring and controlling settings? - High-TeC

niversitair Medisch Centrum Groningen0 个研究点目标入组 158 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
158

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • History of COPD Global Initiative of Obstructive Lung Diseases (GOLD) stage
  • II to IV (FEV1< 80% of predicted with an FEV1/forced vital capacity (FVC) ratio
  • <70), with a history of at least 10 pack years smoking.
  • At least 1 COPD exacerbation in the year prior to the index hospital
  • admission (exacerbation defined as worsening of pulmonary symptoms requiring
  • oral steroids and/or antibiotics and/or hospital admission)
  • Being admitted to the hospital with a COPD exacerbation
  • Written informed consent is obtained

排除标准

  • No lung function data available, • The presence of another acute condition
  • (e.g. pneumonia, acute congestive heart failure, pulmonary embolus) explaining
  • or significantly contributing to the index admission, • Inability to comply
  • with the tests, • The presence of another chronic lung disease (e.g. asthma,
  • restrictive lung disease).
  • Already on non-invasive ventilation or nasal high flow therapy (at home
  • or during the exacerbation)

研究者

相似试验